James L. Mulshine, MD, of Rush University Medical Center, discusses the profound challenges of implementing national CT screening to ensure delivery of high-quality, best-practice early lung cancer detection in the target population of tobacco-exposed individuals (Abstract MS 15.01).
Ugo Pastorino, MD, of the Istituto Nazionale dei Tumori Foundation, discusses his study, which showed that stopping smoking before or during low-dose computed tomography screening reduced overall mortality by more than 25%, a benefit that is three- to fivefold greater than this type of screening (Abstract PLEN04.07).
Roy S. Herbst, MD, PhD, of the Smilow Cancer Hospital at Yale Cancer Center, discusses his findings of a phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in advanced non–small cell lung cancer (Abstract PLEN04.01).
Eric Lim, MD, of the Royal Brompton and Harefield NHS Trust, discusses his findings on the nonspecific symptoms of never-smokers, which suggests that imaging could play a more important role in diagnosing these patients at an earlier stage.
Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, summarizes a workshop he conducted on the state of the art in next-generation sequencing of lung cancer (Abstract WS 01.07).
Barbara J. Gitlitz, MD, of USC/Norris Cancer Center, discusses the first prospective study on the genomic drivers and demographics of lung cancer in patients under 40 who took part in the study remotely via the Internet (Abstract ORAL22.05).
